Cardiac Manifestations of Systemic Lupus Erythematous: An Overview of the Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology and Treatment Options.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
Historique:
pubmed:
30
9
2020
medline:
30
12
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.
Identifiants
pubmed: 32991394
pii: 00045415-202201000-00006
doi: 10.1097/CRD.0000000000000358
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-43Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: The authors have no conflicts of interest to report.
Références
Jain D, Halushka MK. Cardiac pathology of systemic lupus erythematosus. J Clin Pathol. 2009;62:584–592.
Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56:1945–1961.
Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc. 1999;74:275–284.
Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016;18:21.
Hejtmancik MR, Wright JC, Quint R, et al. The cardiovascular manifestations of systemic lupus erythematosus. Am Heart J. 1964;68:119–130.
Nicklin A, Byard RW. Lethal manifestations of systemic lupus erythematosus in a forensic context. J Forensic Sci. 2011;56:423–428.
Dhakal BP, Kim CH, Al-Kindi SG, et al. Heart failure in systemic lupus erythematosus. Trends Cardiovasc Med. 2018;28:187–197.
Brigden W, Bywaters EG, Lessof MH, et al. The heart in systemic lupus erythematosus. Br Heart J. 1960;22:1–16.
Miner JJ, Kim AH. Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 2014;40:51–60.
Tselios K, Urowitz MB. Cardiovascular and pulmonary manifestations of systemic lupus erythematosus. Curr Rheumatol Rev. 2017;13:206–218.
Tincani A, Rebaioli CB, Taglietti M, et al. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford). 2006;45(suppl 4):iv8–iv13.
Perricone C, Ciccacci C, Ceccarelli F, et al. TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics. 2013;65:703–709.
Ciccacci C, Perricone C, Ceccarelli F, et al. A multilocus genetic study in a cohort of Italian SLE patients confirms the association with STAT4 gene and describes a new association with HCP5 gene. PLoS One. 2014;9:e111991.
Ciccacci C, Perricone C, Politi C, et al. A polymorphism upstream MIR1279 gene is associated with pericarditis development in systemic lupus erythematosus and contributes to definition of a genetic risk profile for this complication. Lupus. 2017;26:841–848.
Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14:683–686.
Carette S. Cardiopulmonary manifestations of systemic lupus erythematous. Rheum Dis Clin North Am. 1988;14:135–147.
Morel N, Bonjour M, Le Guern V, et al. Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases. Lupus. 2015;24:1479–1485.
Zhang L, Zhu YL, Li MT, et al. Lupus myocarditis: a Case-Control Study from China. Chin Med J (Engl). 2015;128:2588–2594.
Law WG, Thong BY, Lian TY, et al. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus. 2005;14:827–831.
Wang CR, Tsai YS, Li WT. Lupus myocarditis receiving the rituximab therapy-a monocentric retrospective study. Clin Rheumatol. 2018;37:1701–1707.
Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011;70:760–765.
Ardoin SP, Schanberg LE, Sandborg CI, et al.; APPLE Investigators. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73:557–566.
dos Reis-Neto ET, da Silva AE, Monteiro CM, et al. Supervised physical exercise improves endothelial function in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2013;52:2187–2195.
Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365–1371.
Pengo V, Banzato A, Bison E, et al. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus. 2016;25:301–306.
Keogan M, K G, Jefferies CA. Systemic Lupus Erythematosus. San Diego, CA: Academic Press; 2011.
Costenbader KH, Karlson EW, Gall V, et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum. 2005;53:718–723.
Yan J, Varma SK, Malhotra A, et al. Congenital complete heart block: single tertiary centre experience. Heart Lung Circ. 2012;21:666–670.
Izmirly P, Kim M, Costedoat-Chalumeau N, et al. The prospective open label preventive approach to congenital heart block with hydroxychloroquine (PATCH) study demonstrates a reduction in the recurrence rate of advanced block [abstract]. Arthritis Rheumatol. 2019;71(suppl 10). Available at: https://acrabstracts.org/abstract/the-prospective-open-label-preventive-approach-to-congenital-heart-block-with-hydroxychloroquine-patch-study-demonstrates-a-reduction-in-the-recurrence-rate-of-advanced-block/ . Accessed September 28, 2020.
Friedman DM, Kim MY, Copel JA, et al.; PRIDE Investigators. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008;117:485–493.
Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62:1138–1146.
Appenzeller S, Pineau CA, Clarke AE. Acute lupus myocarditis: clinical features and outcome. Lupus. 2011;20:981–988.
Thomas G, Cohen Aubart F, Chiche L, et al. Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients. J Rheumatol. 2017;44:24–32.
Caforio AL, Pankuweit S, Arbustini E, et al.; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–2648, 2648a.
Baandrup U, Florio RA, Olsen EG. Do endomyocardial biopsies represent the morphology of the rest of the myocardium? A quantitative light microscopic study of single v. multiple biopsies with the King’s bioptome. Eur Heart J. 1982;3:171–178.
Ansari A, Larson PH, Bates HD. Cardiovascular manifestations of systemic lupus erythematosus: current perspective. Prog Cardiovasc Dis. 1985;27:421–434.
Roberts WC, High ST. The heart in systemic lupus erythematosus. Curr Probl Cardiol. 1999;24:1–56.
Nord JE, Shah PK, Rinaldi RZ, et al. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum. 2004;33:336–351.
Griffith GC, Vural IL. Acute and subacute disseminated lupus erythematosus; a correlation of clinical and postmortem findings in eighteen cases. Circulation. 1951;3:492–500.
Zhang L, Zhu YL, Li MT, et al. Lupus myocarditis: a case-control study from China. Chin Med J (Engl). 2015;128:2588–2594.
Moyssakis I, Tektonidou MG, Vasilliou VA, et al. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007;120:636–642.
Vivero F, Gonzalez-Echavarri C, Ruiz-Estevez B, et al. Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimmun Rev. 2016;15:1134–1140.
Perez-Villa F, Font J, Azqueta M, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum. 2005;53:460–467.
Kim CH, Al-Kindi SG, Jandali B, et al. Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2017;103:227–233.
Nikpour M, Urowitz MB, Gladman DD. Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep. 2009;11:248–254.
Zeller CB, Appenzeller S. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Curr Cardiol Rev. 2008;4:116–122.
Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331–2337.
Bruce IN, Gladman DD, Ibañez D, et al. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. J Rheumatol. 2003;30:288–291.
Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176:708–719.
Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408–415.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143.
Croca S, Rahman A. Atherosclerosis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:364–372.
Navab M, Ananthramaiah GM, Reddy ST, et al. The double jeopardy of HDL. Ann Med. 2005;37:173–178.
Mavrogeni S, Koutsogeorgopoulou L, Dimitroulas T, et al. Complementary role of cardiovascular imaging and laboratory indices in early detection of cardiovascular disease in systemic lupus erythematosus. Lupus. 2017;26:227–236.
Kiani AN, Magder LS, Post WS, et al. Coronary calcification in SLE: comparison with the multi-ethnic study of atherosclerosis. Rheumatology (Oxford). 2015;54:1976–1981.
Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus. 2008;17:394–399.
Crow MK. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr Opin Rheumatol. 2014;26:467–474.
Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876–1890.
McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011;7:227–241.
Wigren M, Nilsson J, Kaplan MJ. Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention. J Intern Med. 2015;278:494–506.
Larsson PT, Hallerstam S, Rosfors S, et al. Circulating markers of inflammation are related to carotid artery atherosclerosis. Int Angiol. 2005;24:43–51.
Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275–281.
Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–212.
Gupta S, Pablo AM, Jiang Xc, et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99:2752–2761.
Whitman SC, Ravisankar P, Elam H, et al. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol. 2000;157:1819–1824.
Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE–mechanisms and management. Nat Rev Rheumatol. 2012;8:214–223.
Shin MS, Lee N, Kang I. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol. 2011;23:444–448.
Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol. 2013;62:255–262.
Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004;103:3677–3683.
Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407–2415.
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112:1687–1695.
Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015;54:1244–1249.
Meckler KA, Kapur RP. Congenital heart block and associated cardiac pathology in neonatal lupus syndrome. Pediatr Dev Pathol. 1998;1:136–142.
Saxena A, Izmirly PM, Mendez B, et al. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev. 2014;22:263–267.
Friedman D, Duncanson Lj, Glickstein J, et al. A review of congenital heart block. Images Paediatr Cardiol. 2003;5:36–48.